#1 Clinical Trials Search in Europe

Safety and feasibility study of fecal microbiota transplant in stage II-III non-small cell lung cancer patients treated with durvalumab, carboplatin, paclitaxel and rifaximin

2 1 1 1

What is this study about?

This study focuses on patients with Non-Small Cell Lung Cancer (NSCLC) in stages II-III. The research investigates the safety and effectiveness of fecal microbiota transplant (transfer of stool from one person to another) in combination with several medications. The main treatment includes durvalumab, which is given through an intravenous infusion and works by helping the immune system fight cancer cells.

The treatment plan combines different medications: rifaximin (taken as tablets by mouth), carboplatin, and paclitaxel (both given through intravenous infusion). The study aims to determine if adding stool transplants from patients who have previously responded well to cancer immunotherapy can improve treatment outcomes for new patients.

During the study, patients will receive treatment over several months. The treatment includes regular doses of medications and monitoring of how the cancer responds to therapy. The stool transplant procedure will be performed as part of the treatment process. Doctors will perform various tests and scans throughout the study to check how well the treatment is working and to monitor for any side effects.

1 Initial treatment phase

You will receive durvalumab through an intravenous infusion. This medication helps your immune system fight cancer cells.

You will also receive carboplatin and paclitaxel through intravenous infusions. These are cancer-fighting medications.

Additionally, you will take rifaximin tablets by mouth. This medication affects bacteria in your digestive system.

2 Medical evaluations

Your doctor will perform regular examinations to check how your body responds to the treatment.

You will have CT scans to measure any changes in your lung cancer.

Your blood will be tested regularly to monitor your body’s functions.

3 Surgery phase

After the initial treatment, you will undergo surgery to remove the remaining cancer tissue.

The surgery results will be examined to determine if any cancer cells remain in your lungs or lymph nodes.

4 Follow-up period

Your health will be monitored for up to 24 months after treatment.

Regular check-ups will track your recovery and any signs of cancer returning.

Side effects will be recorded and treated as needed.

5 Safety requirements

If you can have children, you must use effective birth control during the study and for 6 months after the last treatment.

Regular pregnancy tests will be required for women who can become pregnant.

You will need to attend all scheduled appointments and follow the treatment plan as prescribed.

Who Can Join the Study?

  • Must be at least 18 years old
  • Must have previously untreated non-small cell lung cancer at stages IIA, IIB, IIIA, or IIIB
  • Must have no signs of cancer spread to distant parts of the body (confirmed by PET scan and brain CT or MRI)
  • Must be in good overall physical condition (ECOG score of 0-1, meaning able to perform daily activities)
  • Must have adequate blood test results showing good organ function
  • Must have good lung function test results
  • Must weigh more than 30 kg
  • Must have had PDL1 testing completed (a test that helps determine treatment options)
  • Must have at least one tumor that can be measured by CT scan
  • Must have a life expectancy of at least 12 weeks
  • Must be willing to follow study requirements and attend all scheduled visits
  • Must provide written informed consent to participate in the study
  • For women who can become pregnant: Must have a negative pregnancy test and use effective birth control during the study and for 6 months after
  • For men with partners who can become pregnant: Must use effective birth control including condoms during the study and for 6 months after

Who Cannot Join the Study?

  • Prior treatment with chemotherapy (medications used to kill cancer cells) for lung cancer
  • History of other cancers in the past 5 years, except for successfully treated skin cancer or cervical cancer
  • Serious heart conditions including heart failure (when heart cannot pump blood effectively) or recent heart attack within 6 months
  • Severe kidney or liver problems
  • Active or untreated brain metastases (cancer that has spread to the brain)
  • Current pregnancy or breastfeeding
  • Known allergies to study medications
  • Autoimmune diseases (conditions where immune system attacks healthy cells)
  • Active infections requiring treatment
  • Participation in other clinical trials within 30 days
  • Mental conditions that could interfere with following study procedures
  • Use of medications that could interact with study treatment
  • History of organ transplantation
  • Uncontrolled high blood pressure
  • Active bleeding problems or conditions requiring blood thinners

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario Y Politecnico La Fe Valencia Spain
Hospital Clinico San Carlos Madrid Spain

Other Sites

Site Name City Country Status
Hospital Universitario Puerta De Hierro De Majadahonda Majadahonda Spain
Hospital Universitario 12 De Octubre Madrid Spain
Hospital General Universitario Morales Meseguer Murcia Spain
Hospital Universitari Dexeus Grupo Quironsalud Barcelona Spain
Hospital Universitario Fundacion Jimenez Diaz Madrid Spain
Universidade De Santiago De Compostela Santiago De Compostela Spain
Hospital Universitario Lucus Augusti Lugo Spain
Iadqamxo Cjrmvz Djrupjvyflfokfhot L'hospitalet De Llobregat Spain
Clszihgd Hfvehweurgws Uhrnoxkojgcsc Dj Vwap Vigo Spain
Hvjkpzex Dk Lk Sqtqn Crfa I Saxc Pur Barcelona Spain
Habmgfpy Vuka dyprypxo Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Recruiting
15.12.2025

Trial locations

Investigated drugs:

Fecal Microbiota Transplant (FMT)
This is a procedure where fecal matter from a healthy donor is processed and transferred to a recipient. In this trial, the donors are patients who have responded well to immune checkpoint inhibitor therapy. The transplant aims to modify the gut microbiome of the recipient, which may influence how the body responds to cancer treatment.

Immune Checkpoint Inhibitors (ICI)
These are medications that help the immune system recognize and attack cancer cells. They work by blocking certain proteins that normally prevent the immune system from attacking cancer cells. In this trial, they are used in the treatment of non-small cell lung cancer, and patients who respond well to this therapy serve as donors for the fecal microbiota transplant.

Investigated diseases:

Non-Small Cell Lung Cancer – A type of lung cancer that begins in the cells of the lungs and forms as a mass of cancerous cells that grows larger over time. It develops when healthy cells in the lung tissue begin to change and grow uncontrollably, forming a tumor. The cancer typically starts in the cells that line the airways of the lungs (bronchi). This disease progresses gradually, spreading first within the lung itself and potentially to nearby lymph nodes. It is the most common form of lung cancer, accounting for about 85% of all lung cancers.

Trial ID:
2025-521251-24-00
Protocol code:
GECP 24/02_MIGRANT
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of MK-1084 plus durvalumab in patients with locally advanced unresected KRAS G12C‑mutated non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated drugs:
    France Germany Greece Italy The Netherlands Poland +1

  • Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain